Search Results - "Gute, P"

Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co‐administration by Bickel, M, Khaykin, P, Stephan, C, Schmidt, K, Buettner, M, Amann, K, Lutz, T, Gute, P, Haberl, A, Geiger, H, Brodt, HR, Jung, O

“…Objectives The renal elimination of tenofovir (TFV) may be subject to renal drug−drug interactions that may increase the risk of kidney injury. Case reports…”
Get full text

End‐stage renal disease and dialysis in HIV‐positive patients: observations from a long‐term cohort study with a follow‐up of 22 years by Bickel, M, Marben, W, Betz, C, Khaykin, P, Stephan, C, Gute, P, Haberl, A, Knecht, G, Wolf, T, Brodt, HR, Geiger, H, Herrmann, E, Jung, O

“…Objectives Renal disease is a common and serious complication in HIV‐infected patients. Methods A retrospective cohort analysis for the period 1989–2010 was…”
Get full text

P0721 : Viral and host parameters in association with outcome of acute hepatitis C in HIV-coinfected patients by Dietz, J, Lutz, T, Knecht, G, Gute, P, Berkowski, C, Lange, C.M, Khaykin, P, Stephan, C, Brodt, H.-R, Zeuzem, S, Sarrazin, C

Get full text

Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysis by Wolf, T., Fuß, B., Khaykin, P., Berger, A., Knecht, G., Gute, P., Brodt, H. R., Goepel, S., Bickel, M., Stuermer, M., Stephan, C.

“…To evaluate the treatment outcome of antiretroviral therapy, depending on the use and utility of a concept of resistance-guided switch, patients from the…”
Get full text

First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe Aplastic Anemia by Wolf, T, Rickerts, V, Staszewski, S, Kriener, S, Wassmann, B, Bug, G, Bickel, M, Gute, P, Brodt, H.R, Martin, H

“…1 From the: Department of Infectious Diseases 2 HIV Center 3 Department of Hematology/Oncoloy 4 Department of Pathology, Hospital of the Johann Wolfgang Goethe…”
Get full text

1104 ANALYSIS OF VIRAL FACTORS, CLINICAL PARAMETERS AND IL28B ASSOCIATED WITH OUTCOME OF PATIENTS WITH ACUTE HEPATITIS C AND HIV COINFECTION by Dietz, J, Lutz, T, Knecht, G, Gute, P, Carlebach, A, Grammatikos, G, Füller, C, Raziorrouh, B, Diepolder, H, Hofmann, W.P, Stephan, C, Brodt, H.R, Zeuzem, S, Sarrazin, C

Get full text

The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy by Staszewski, Schlomo, Babacan, Errol, Stephan, Christoph, Haberl, Annette, Carlebach, Amina, Gute, Peter, Klauke, Stephan, Hermschulte, Yvonne, Stuermer, Martin, Dauer, Brenda

“…Objectives: To evaluate the virological, immunological and clinical responses to the boosted double protease inhibitor (PI) regimen combination of…”
Get full text

1325 CHARACTERISTICS OF ACUTE HEPATITIS C IN A HIV-COINFECTED COHORT: ANALYSIS OF IL28B AND VIRAL FACTORS ASSOCIATED WITH OUTCOME by Dietz, J, Lutz, T, Knecht, G, Gute, P, Grammatikos, G, Füller, C, Raziorrouh, B, Diepolder, H, Hofmann, W.P, Zeuzem, S, Sarrazin, C

Get full text

1055 SEQUENCE EVOLUTION OF THE HCV NS3/4A PROTEASE DURING ACUTE HEPATITIS C VIRUS (HCV) INFECTION by Dietz, J, Lutz, T, Knecht, G, Gute, P, Nehring, A, Raziorrouh, B, Diepolder, H, Zeuzem, S, Sarrazin, C

Get full text

Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients by Bickel, M., Bodtländer, A., Knecht, G. K., Stephan, C., von Hentig, N., Kurowski, M., Gute, P., Klauke, S., Lutz, T.

“…Objectives To investigate the feasibility and pharmacokinetics of a once-daily regimen of 2000 mg saquinavir mesylate boosted with 100 mg ritonavir. Patients…”
Get full text

Drug Resistance to Tipranavir (TPV) or Darunavir (DRV) According to New Interpretation Algorithms in PI-naïve HIV-1 Infected Patients by Stuermer, M., Dauer, B., Haberl, A., Mueller, A., Gute, P., Klauke, S., Staszewski, S., Doerr, H.W.

Get full text

First‐line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48‐week results by Voigt, E, Wickesberg, A, Wasmuth, J‐C, Gute, P, Locher, L, Salzberger, B, Wöhrmann, A, Adam, A, Weitner, L, Rockstroh, JK

“…Objectives To evaluate safety and efficacy of the protease inhibitor combination ritonavir/indinavir 100/800 mg twice daily plus 2–3 nucleoside reverse…”
Get full text

Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients by Salzberger, B, Däumer, M, Gute, P, Jaeger, H, Knechten, H, van Lunzen, J, Mauss, S, Mayr, C, Moll, A, Plettenberg, A, Rockstroh, J, Staszewski, S, Stellbrink, H J, Stoll, M, Sturmer, M

“…The EU approval of enfuvirtide (Fuzeon) was granted in May 2003 on the basis of the 48-week data from the TORO 1 and TORO 2 studies. Enfuvirtide is licensed…”
Get more information

A simple, once‐daily dosing regimen for treating HIV‐1 infection in intravenous drug users by Staszewski, S, Haberl, A, Carlebach, A, Rottmann, C, Miller, V, Gute, P

Get full text

Is transmission of HIV-1 in non-viraemic serodiscordant couples possible? by VERNAZZA, Pietro L, HIRSCHEL, Bernard, STÜRMER, Martin, DOERR, Hans W, BERGER, Annemarie, GUTE, Peter

“…Several studies have shown that HIV-1 transmission in serodiscordant couples is significantly reduced when the plasma viral load (pVL) in the infected partner…”
Get full text

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure by MILLER, Veronica, SABIN, Caroline, RABENAU, Holger, PHILLIPS, Andrew, STASZEWSKI, Schlomo, HERTOGS, Kurt, BLOOR, Stuart, MARTINEZ-PICADO, Javier, D'AQUILA, Richard, LARDER, Brendan, LUTZ, Thomas, GUTE, Peter, WEIDMANN, Eckhart

“…To analyse the immunological and virological effects of treatment interruptions in HIV-1-infected patients with treatment failure and multidrug-resistant…”
Get full text

Improved Virological and Immunological Efficacy of Resistance-Guided Switch in Anti- retroviral Therapy: A Frankfurt HIV Cohort Analysis by Wolf, T, Fuß, B, Khaykin, P, Berger, A, Knecht, G, Gute, P, Brodt, HR, Goepel, S, Bickel, M, Stuermer, M, Stephan, C

“…To evaluate the treatment outcome of antiretroviral therapy, depending on the use and utility of a concept of resistance-guided switch, patients from the…”
Get full text

Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy by BRODT, H. R, KAMPS, B. S, GUTE, P, KNUPP, B, STASZEWSKI, S, HELM, E. B

“…To determine the incidence of AIDS-defining opportunistic infections and malignancies over a 5-year period from 1992 to 1996. Subcohort of 1003 homosexual men…”
Get full text

Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo by Graff, Jochen, von Hentig, Nils, Kuczka, Karina, Angioni, Carlo, Gute, Peter, Klauke, Stefan, Babacan, Errol, Harder, Sebastian

“…Objectives In the past, bleeding events have been described for patients with haemophilia taking HIV-1 protease inhibitors. Recently, the FDA published a…”
Get full text

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy by STASZEWSKI, S, MILLER, V, PHILLIPS, A, SABIN, C, SCHLECHT, C, GUTE, P, STAMM, S, LEDER, T, BERGER, A, WEIDEMANN, E, HILL, A

“…HIV-induced CD4 lymphocyte depletion is partially reversed by antiretroviral therapy but it is unclear if the degree to which the CD4 count rises depends on…”
Get full text